Tessa Janovsky
PA-C
Location : Phoenix, Arizona, USA
BIO
Tessa Janovsky obtained her Masters in Physician Assistant Studies from Rosalind Franklin University of Medicine and Science in 2017. She accepted a position in the Gastroenterology Department at Valleywise Health in 2017 where her passion for Liver Disease was born with special interest in MASLD/MASH. Caring for a primarily underserved population with a large proportion of Hispanic patients, Tessa quickly realized that there were gaps in timely diagnosis and proper treatment for MASLD/MASH patients. Her interest in liver disease led her to accept a position at Banner University Liver Transplant Center where she would gain knowledge and experience in liver transplant selection and post liver transplant care. During that time, Tessa obtained a certification in Obesity Management from the Obesity Medicine Association with a goal to help patients optimize their journey with weight loss, which is a primary focus in MASLD/MASH treatment.
Tessa now practices in an outpatient Hepatology Clinic at Arizona Liver Health, where she has been for the past 3 years. With a primary focus on patients with MASLD/MASH, she strives to take an individualized approach with each patient to optimize treatment strategies, including lifestyle interventions, pharmacologic management, and clinical trial opportunities.
MASLD-MASH Content Featuring Tessa
Webcast: MASLD vs MetALD With Tessa Janovsky
September 2025
Tessa Janovsky, PA-C, Arizona Liver Health, delivers a clear, case-based overview of metabolic dysfunction–associated steatotic liver disease (MASLD), MASH, and mixed-etiology MET-ALD. Using a common clinic scenario, she explains how to recognize fatty liver on imaging, why an accurate alcohol history matters, and how non-invasive tools (FibroScan stiffness/CAP and alcohol biomarkers like PEth) guide staging and care. You’ll learn practical, patient-friendly steps—Mediterranean-style nutrition, sustainable weight loss, regular aerobic and resistance exercise, and alcohol cessation—plus when to consider medications, specialist referral, and ongoing surveillance to prevent progression to advanced fibrosis and cirrhosis. Ideal for APPs and GI clinicians seeking straightforward strategies to manage MASLD/MASH in everyday practice.
Watch Now
Webcast: MASLD Pharmacotherapy With Tessa Janovsky
September 2025
Join Tessa Janovsky, PA-C from Arizona Liver for a practical update on MASLD pharmacotherapy—from whole-patient metabolic management to liver-directed treatment. This session reviews why care must target the entire metabolic syndrome (weight, type 2 diabetes, hypertension, dyslipidemia, cardiovascular risk), the impact of 7–10% weight loss (and why many patients need adjuncts), and how to choose between diet/physical activity, anti-obesity medications, and bariatric surgery for select cases. You’ll learn where GLP-1 receptor agonists fit (mechanism, expected weight and glycemic effects, GI side effects, peri-procedure anesthesia considerations, and use in compensated disease), when to use statins safely in fatty liver, and how to stage and monitor with FIB-4, FibroScan/elastography, and other non-invasive tests. Tessa also summarizes legacy data for vitamin E and pioglitazone (benefits and limitations) and highlights the first FDA-approved therapy for non-cirrhotic MASH with F2–F3 fibrosis, resmetirom—including mechanism (THR-β agonism), tolerability, drug–drug interaction checkpoints, and practical follow-up (restaging and lifestyle coaching). If you’re a GI/hepatology clinician or APP aiming to streamline risk reduction, staging, and evidence-based therapy for MASLD/MASH, this concise talk delivers clinic-ready guidance.
Watch Now
PCP Screening for MASH/MASLD: Identifying At-Risk Patients
August 2025
Join Tessa Janovsky, PA-C from Arizona Liver Health, for a practical and guideline-based discussion on screening for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) in primary care. This session outlines which patient populations Advanced Practice Providers (APPs) should routinely screen—such as individuals with type 2 diabetes, medically complicated obesity, metabolic risk factors with fatty liver on imaging, moderate alcohol use (MetALD), or a family history of MASH cirrhosis. Learn how to apply first-line non-invasive screening tools like FIB-4 and the NAFLD Fibrosis Score, understand their limitations, and incorporate them into busy clinic workflows. Tessa shares strategies for communicating positive results to patients, next steps for further evaluation (ELF test, FibroScan, MRI elastography), and criteria for timely referral to gastroenterology or hepatology. With practical tips for integrating MASLD/MASH screening into electronic medical records, building clinical pathways, and standardizing protocols, this episode equips PCPs and specialists to detect high-risk patients earlier, intervene effectively, and ultimately improve liver health outcomes.
Watch Now
Common Questions From Primary Care Providers About MASH
August 2025
In this MASLD and MASH Community Network, Tessa Janovsky, PA-C at Arizona Liver Health, answers common questions from primary care providers about Metabolic Dysfunction–Associated Steatohepatitis (MASH) and its updated terminology. She explains why MASH has replaced the term NASH, highlighting the shift to reflect underlying metabolic drivers such as obesity and type 2 diabetes while removing stigmatizing language. Tessa discusses how normal or mildly elevated liver enzymes do not rule out MASH, the importance of screening high-risk groups—including patients with diabetes, obesity, metabolic syndrome, or incidental fatty liver on imaging—and why the FIB-4 score is the preferred first-line test for fibrosis risk assessment. She also reviews the first FDA-approved medication for MASH, resmetirom, as well as the role of GLP-1 therapies and upcoming treatment options. Whether you’re a clinician seeking updated screening guidelines or a patient wanting clarity on diagnosis and management, this session provides clear, evidence-based guidance on identifying and treating MASH.
Watch Now
Webcast: MASLD Basics With Tessa Janovsky
August 2025
Join Tessa Janovsky, PA-C, from Arizona Liver Health, for this foundational session in the GHAPP MASLD Community Network, proudly sponsored by Madrigal Pharmaceuticals. This episode offers a comprehensive overview of the updated nomenclature and clinical approach to steatotic liver disease, covering the transition from NAFLD/NASH to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and MASH (Metabolic Dysfunction-Associated Steatohepatitis). Tessa breaks down the rationale behind this global reclassification and explains how it improves diagnostic clarity while reducing stigma. You’ll learn how to identify MASLD using cardiometabolic risk factors, apply non-invasive risk stratification tools like FIB-4, FibroScan, and ELF, and determine when to refer patients for hepatology care. She also discusses the natural history of MASLD progression, the risk of cirrhosis and HCC, and the clinical importance of early detection and treatment. Real-world case studies guide providers through assessing common patient presentations, ruling out alternative etiologies, and considering pharmacologic therapy like resmetirom when appropriate. This is an essential watch for APPs, PCPs, and GI providers working to better understand and manage MASLD and MASH in clinical practice.
Watch Now
Management of Lifestyle Modification
January 2025
This video focuses on the comprehensive management of patients with metabolic-associated steatohepatitis (MASH), emphasizing lifestyle modifications, dietary adjustments, and exercise strategies. Key topics include the importance of addressing risk factors like diet, exercise habits, and alcohol intake, as well as referrals to medically supervised weight loss clinics or bariatric surgery for advanced cases. The speaker highlights the benefits of the Mediterranean diet, intermittent fasting, and avoiding ultra-processed foods while discussing the role of resistance training to combat sarcopenia and maintain muscle mass. Practical advice and tailored recommendations ensure a holistic approach to managing MASH and improving patient outcomes.
Watch Now
Third Step of Lifestyle Management
January 2025
This video provides a comprehensive overview of emerging pharmacologic treatments for metabolic-associated steatohepatitis (MASH) and their tailored applications based on patient profiles. Topics include FDA-approved therapies, drugs in advanced clinical trials (such as semaglutide and lanifibranor), and the potential for combination treatments targeting both steatohepatitis and fibrosis. The speaker emphasizes the importance of patient-specific approaches considering metabolic profiles, obesity, and diabetes status, alongside lifestyle interventions. Additionally, the video discusses the evolving interdisciplinary care model and highlights the exciting progress in non-invasive testing and treatment advancements for F2-F3 fibrosis.
Watch Now
Approved Medication for MASH/NASH
January 2025
This video provides detailed guidance on selecting and monitoring patients for emerging therapies targeting advanced fibrosis (F2-F3) in NASH. Key topics include contraindications for patients with cirrhosis, considerations for concomitant medications, and dose adjustments for statins. The video outlines ideal candidates based on specific thresholds for VCTE, MRE, ELF scores, and other non-invasive tests while emphasizing the importance of ruling out portal hypertension and other liver diseases. It also reviews a stepwise monitoring approach, focusing on tolerability at three months and efficacy assessments at six and twelve months, with an emphasis on histologic and non-invasive test improvements.
Watch Now
Types of Diet for the Treatment of MASLD
January 2025
This video explores comprehensive strategies for managing metabolic-associated steatohepatitis (MASH), focusing on fibrosis risk stratification, lifestyle modifications, and pharmacologic interventions. Learn about dietary recommendations like the Mediterranean diet, exercise guidelines emphasizing resistance training, and the role of intermittent fasting and processed food avoidance. The video also highlights weight loss targets, diabetes management, and emerging therapies such as GLP-1 receptor agonists and bariatric surgery, all aimed at improving liver health and patient outcomes.
Watch Now
NITs to Identify High Risk MASH Patients
January 2025
Explore advancements in non-invasive diagnostics and risk stratification for liver fibrosis and MASH. This video highlights tools like FIB-4, transient elastography, and innovative scoring systems (e.g., FAST and Agile) to identify and predict outcomes for high-risk patients. Learn about serum biomarkers, updated guidelines, and the role of lifestyle interventions alongside targeted therapies for managing metabolic risks and advancing care in hepatology.
Watch Now
Click the arrows to view more content
